| 15 |
Liang QL，Wang BR，Chen GQ，et al.Clinical significance of vascular endothelial growth factor and connexin43 for predicting pancreatic cancer clinicopathologic parameters[J]．Med Oncol，2010，27(4):1164-1170.
|
| 16 |
Kindler H L，Niedzwiecki D，Hollis D，et al.Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer：Phase III Trial of the Cancer and Leukemia Group B(CALGB 80303)[J]．J Clin Oncol，2010，28(22):3617-3622.
|
| 17 |
Lin WC，Rajbhandari N，Liu C，et al.Dormant cancer cells contribute to residual disease in a model of reversible pancreatic cancer[J]．Cancer Res，2013，73(6):1821-1830.
|
| 18 |
Rajbhandari N，Lin W，Wehde BL，et al.Autocrine IGF1 signaling mediates pancreatic tumor cell dormancy in the absence of oncogenic drivers[J]．Cell Rep，2011，18(9):2243-2255.
|
| 19 |
Anonymous.Insulin like growth factor-1 receptor and insulin receptor double inhibitor anti-cancer drug Linsitinib[J]．Pharmacological Progress，2013，37(4)．
|
| 20 |
Hai H，Han T，Meng Z，et al.Elevated COX-2 Expression Promotes Angiogenesis Through EGFR/p38-MAPK/Sp1-Dependent Signalling in Pancreatic Cancer[J]．Sci Rep，2017，7(1):470.
|
| 21 |
Lipton A，Campbellbaird C，Witters L，et al.Phase II trial of gemcitabine，irinotecan，and celecoxib in patients with advanced pancreatic cancer[J]．J Clin Gastroenterol，2010，44(4):286.
|
| 22 |
Knapinska AM，Estrada CA，Fields GB.The Roles of Matrix Metalloproteinases in Pancreatic Cancer[J]．Prog Mol Biol Transl Sci，2017，148:339-354.
|
| 23 |
Huaiyong XU，Gong B，Gao C，et al.Effects of a new matrix metalloproteinase inhibitor，MMI-166，in nude mouse xenografts of human pancreatic cancer[J]．Chin J Hepatobili Surg，2012，18(11):859-862.
|
| 24 |
Chen YJ，Wang WH，Wu WY，et al.Novel histone deacetylase inhibitor AR-42 exhibits antitumor activity in pancreatic cancer cells by affecting multiple biochemical pathways[J]．PLos One，2017，12(8):e0183368.
|
| 25 |
Pourmorteza M，Rahman Z U，Young M．Evofosfamide，a new horizon in the treatment of pancreatic cancer[J]．Anti-cancer Drugs，2016，27(8):723-725.
|
| 26 |
Picollo A，Malvezzi M，Accardi A．TMEM16 proteins：unknown structure and confusing functions[J]．J Mol Biol，2015，427(1):94-105.
|
| 27 |
Jun I，Park H S，Piao H，et al.ANO9/TMEM16J promotes tumourigenesis via EGFR and is a novel therapeutic target for pancreatic cancer[J]．Br J Cancer，2017，117(12):1798-1809.
|
| 28 |
Yang T，Rycaj K．Targeted therapy against cancer stem cells[J]．Oncol Let，2015，10(1):27.
|
| 29 |
Ercan G，Karlitepe A，Ozpolat B．Pancreatic Cancer Stem Cells and Therapeutic Approaches[J]．Anticancer Res，2017，37(6):2761-2775.
|
| 30 |
Suzuki S，Okada M，Shibuya K，et al.JNK suppression of chemotherapeutic agents-induced ROS confers chemoresistance on pancreatic cancer stem cells[J]．Oncotarget，2015，6(1):458.
|
| 31 |
Ercan G, Karlitepe A, Ozpolat B．Pancreatic Cancer Stem Cells and Therapeutic Approaches[J]．Anticancer Res，2017，37(6):2761-2775.
|
| 32 |
Bao B，Azmi AS，Ali S，et al.Metformin may function as anti-cancer agent via targeting cancer stem cells：the potential biological significance of tumor-associated miRNAs in breast and pancreatic cancers[J]．Ann Translat Med，2014，2(6):59.
|
| 33 |
Manzur A，Oluwasanmi A，Moss D，et al.Nanotechnologies in Pancreatic Cancer Therapy[J]．Pharmaceutics，2017，9(4):39.
|
| 34 |
Greish K．Enhanced permeability and retention(EPR)effect for anticancer nanomedicine drug targeting[J]．Methods Mol Biol，2010，624:25-37.
|
| 35 |
Longmire M，Choyke PL，Kobayashi H．Clearance properties of nano-sized particles and molecules as imaging agents：considerations and caveats[J]．Nanomedicine，2008，3(5):703-717.
|
| 1 |
Siegel RL，Ma J，Zou Z，et al.Cancer statistics 2014[J]．CA Cancer J Clin，2014，64(1):9-29.
|
| 2 |
Tempero MA，Malafa MP，Al-Hawary M，et al.Pancreatic Adenocarcinoma，Version 2.2017，NCCN Clinical Practice Guidelines in Oncology[J]．J Natl Compr Canc Netw，2017，15(8):1028-1061.
|
| 3 |
Tol JA，Gouma DJ，Bassi C，et al.Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma：A consensus statement by the International Study Group on Pancreatic Surgery(ISGPS)[J]．Surgery，2014，156(3):591-600.
|
| 4 |
Oettle H，Neuhaus P，Hochhaus A，et al.Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer：the CONKO-001 rando-mized trial[J]．JAMA，2013，310(14):1473-1481.
|
| 5 |
Goldstein D，El-Maraghi R H，Hammel P，et al.nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer：long-term survival from a phase III trial[J]．J Natl Cancer Inst，2015，107(2).pii:dju413.
|
| 6 |
Nanda RH，El-Rayes B，Maithel SK，et al.Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability[J]．J Surg Oncol，2015，111(8):1028-1034.
|
| 7 |
Dholakia AS，Chaudhry M，Leal JP，et al.Baseline metabolic tumor volume and total lesion glycolysis are associated with survival outcomes in patients with locally advanced pancreatic cancer receiving stereotactic body radiation therapy[J]．Int J Radiat Oncol Biol Physics，2014，89(3):539-546.
|
| 8 |
Son SH，Song JH，Choi BO，et al.The technical feasibility of an image-guided intensity-modulated radiotherapy(IG-IMRT)to perform a hypofractionated schedule in terms of toxicity and local control for patients with locally advanced or recurrent pancreatic cancer[J]．Radiat Oncol，2012，7(1):203-203.
|
| 9 |
Lin JC，Jen YM，Li M H，et al.Comparing outcomes of stereotactic body radiotherapy with intensity-modulated radiotherapy for patients with locally advanced unresectable pancreatic cancer[J]．Eur J Gastroenterol Hepatol，2015，27(3):259-264.
|
| 10 |
Andrikou K，Peterle C，Pipitone S，et al.Emerging antibodies for the treatment of pancreatic cancer[J]．Expert Opinion Emerging Drugs，2017，22(1):39.
|
| 11 |
Jiade L．Molecular targeting therapy for advanced pancreatic cancer[J]．Chin J Cancer，2009，19(8):590-596.
|
| 12 |
Bournet B，Muscari F，Buscail C，et al.KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma[J]．Clin Transl Gastroenterol，2016，7(3):e157.
|
| 36 |
Cho EC，Glaus C，Chen J，et al.Inorganic nanoparticle-based contrast agents for molecular imaging[J]．Trends Mol Med，2010，16(12):561-573.
|
| 13 |
Neuzillet C，Hammel P，Tijerasraballand A，et al.Targeting the Ras-ERK pathway in pancreatic adenocarcinoma[J]．Cancer Metastasis Rev，2013，32(1/2):147-162.
|
| 14 |
Costache M I，Ioana M，Iordache S，et al.VEGF Expression in Pancreatic Cancer and Other Malignancies：A Review of the Literature[J]．Rom J Intern Med，2015，53(3):199-208.
|